Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Impact of Sustained virological response (SVR) on the liver fibrosis regression in HCV infected patients after the Direct-acting antiviral therapy (DAA)

Trial Profile

Impact of Sustained virological response (SVR) on the liver fibrosis regression in HCV infected patients after the Direct-acting antiviral therapy (DAA)

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Dec 2018

At a glance

  • Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Dec 2018 New trial record
    • 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top